Roche reports OS data for PD-L1 mAb in bladder cancer

Roche (SIX:ROG; OTCQX:RHHBY) reported the first overall survival data from a cohort of patients in the open-label, single-arm Phase II IMvigor 210 trial of atezolizumab ( MPDL3280A) to treat locally advanced or metastatic urothelial bladder cancer. Among 310 patients who had progressed after receiving platinum-based chemotherapy, the mAb against PD-L1 led to a median OS, a secondary endpoint, of 7.9 months. Median OS in a subset of patients with high PD-L1 expression was 11.4 months.

Last July, Roche said atezolizumab met the primary endpoint of overall response rate (ORR) in the same cohort of patients. On Friday, Roche said ORR at a median follow-up of 11.7 months was 15%, and median progression-free survival (PFS), another secondary endpoint, is 2.1 months. The median duration of response has not yet been reached in the cohort. ...